Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06895681 · ClinicalTrials.gov registry record
UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations
A clinical trial, sponsored by University of California, San Francisco.
- Not yet
- Registry status
- 50,000
- Enrollment target
NCT06895681: Clinical Trial study, sponsored by University of California, San Francisco.
NCT06895681 is a clinical trial that has not yet begun recruiting, run by University of California, San Francisco. The registered enrollment target is 50,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06895681 has not yet begun recruiting, sponsored by University of California, San Francisco.
- NOT YET RECRUITING
- Registry status
- 50,000 participants
- Enrollment target
Study Summary
This is a non-therapeutic clinical research biorepository protocol designed to obtain, store, and clinically annotate biospecimens from participants with hereditary cancers. Those biospecimens will be used to generate participant-derived tumor models that will serve as a resource to better understand hereditary cancers and develop new efficient therapies.
Interventions
- OTHER Medical Chart Review
- PROCEDURE Blood Sample
- PROCEDURE Tissue Sample
- PROCEDURE Excess fluid Sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50,000 participants |
| Start Date | 2026-08-31 |
| Est. Completion | 2035-12-31 |
What is known before NCT06895681 opens enrollment
NCT06895681 is an observational study that tracks outcomes without assigning an intervention. Its 50,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 4 interventions - of which Medical Chart Review is the first listed.
NCT06895681 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06895681 about?
NCT06895681 is a clinical study titled "UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations". This is a non-therapeutic clinical research biorepository protocol designed to obtain, store, and clinically annotate biospecimens from participants with hereditary cancers. Those biospecimens will be used to generate participant-derived tumor models that will serve as a resource to better understan...
What is the current status of trial NCT06895681?
This trial is currently not yet recruiting. The enrollment target is 50,000 participants. The study started on 2026-08-31. Estimated completion is 2035-12-31.
What interventions are being tested in trial NCT06895681?
The interventions under investigation include: Medical Chart Review (OTHER), Blood Sample (PROCEDURE), Tissue Sample (PROCEDURE), Excess fluid Sample (PROCEDURE).
Who is sponsoring clinical trial NCT06895681?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00500123 · 50,000 participants
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
- NCT01885299 · 50,000 participants
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
- NCT03452774 · 50,000 participants
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- NCT04629586 · 50,000 participants
The T1D Exchange Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI